Abstract
This article describes in a sequential fashion how ab initio quantum mechanical methods can be applied to study the pharmacophoric features of drugs. It also describes how accurate drug–receptor interaction calculations can guide the careful design of balanced dual inhibitors, which form an important class of second generation drugs. As an example, the authors have chosen balanced inhibitors of angiotensin converting enzyme/neutral endopeptidase (ACE/NEP) as modern antihypertensive drugs. A unified, accurate, in silico design approach is presented, encompassing all steps from pharmacophore derivation to complete understanding of mechanistic aspects leading to drug design.
Similar content being viewed by others
References
Patrick G (ed) (2002) In: Medicinal Chemistry. BIOS Scientific, Oxford, pp 221–241
Cushman DW, Ondetti MA (1999) Nat Med 5:1110–1113
Ondetti MA (1994) Annu Rev Pharmacol Toxicol 34:1–16
Gupta SP (ed) (2006) QSAR and molecular modeling studies in heterocyclic drugs II. Springer, Berlin
Crippen GM (2008) Curr Comp Aided Drug Des 4:259–264
Zhou P, Tian F, Wu Y, Li Z, Shang Z (2008) Curr Comp Aided Drug Des 4:311–321
Meng EC, Shoichet BK, Kuntz ID (1992) J Comp Chem 13:505–524
Breda A, Basso LA, Santos DS, de Azevedo Jr WF (2008) Curr Comp Aided Drug Des 4:265–272
Dalton JA, Jackson RM (2007) Bioinformatics 23:1901–1908
Waszkowycz B, Perkins TDJ, Sykes RA, Li J (2001) IBM Syst J 40:360–378
Zhorov BS (1997) Arch Biochem Biophys 341:238–244
Yadav A, Singh SK (2005) THEOCHEM 723:205–209
Jain S, Yadav A (2008) Chem Biol Drug Des 71:271–277
Jandeleit-Dahm K (2006) J Hum Hypertens 20:478–481
Opie LH (1992) Angiotensin converting enzyme inhibitors. Wiley-Lisa, New York
Edwards C (1985) Lancet 325:30–34
Jackson B, Cubela RB, Conway EL, Johnston CI (1988) J Clin Pharmacol 25:719–724
Acharya KR, Sturrock ED, Riordan JF, Ehlers MRW (2003) Nat Rev Drug Disc 2:891–902
Molinaro G, Cugno M, Perez M, Lepage Y, Gervais N, Agostoni A, Adam A (2002) J Pharmacol Exp Ther 303:232–237
Johnston CI, Hodsman PG, Kohzuki M, Casley DJ, Fabris B, Phillips PA (1989) Am J Med 87:24S–28S
Wei L, Clauser E, Alhenc Gelas F, Corvol P (1992) J Biol Chem 267:13398–13405
Ehler MR, Riordan JF (1991) Biochemistry 30:7118–7126
Georgiadis D, Beau F, Czarny B, Cotton I, Yiotakis A, Dive V (2003) Circ Res 93:148–154
Dive V, Cotton J, Yiotakis A, Michaud A, Vassiliou S, Jiracek J, Vazeux G, Chauvet MT, Cuniasse P, Corvol P (1999) Proc Natl Acad Sci USA 96:4330–4335
Georgiadis D, Cuniasse P, Cotton J, Yiotakis A, Dive V (2004) Biochemistry 43:8048–8054
Laurent S, Boutouyrie P, Azizi M, Marie C, Gros C, Schwartz JC, Lecomte JM, Bralet J (2000) Hypertension 35:1148–1153
Weber M (1999) Am J Hypertens 12:139S–147S
Leung D, Abbenante G, Fairlie DP (2000) J Med Chem 43:305–341
Chevillard C, Jouquey S, Bree F, Mathieu M N, Stepniewski J P, Tillement JP, Hamon G, Corvol PJ (1994) Cardiovasc Pharmacol 4[suppl 23]:S1L–SL5
Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE (2004) Acta Crystallogr D 60:392–396
Marie-Claire C, Ruffet E, Antonczak S, Beaumont A, Donohue MO, Fournie-Zaluski MC (1997) J Biochem 36:13938–13945
Barthelmebs M, Devissaquet M, Imbs JL (1989) Clin Exp Hypertens A11 [Suppl 2]:471–486
Sagnella GA (2002) J Renin Angiotensin Aldosterone Syst 3:90–95
Bralet J, Schwartz JC (2001) Trends Pharmacol Sci 22:106–109
Molineux G, Rouleau J, Adam A (2002) Curr Opin Pharmacol 2:131–141
Peng C, Ayala PY, Schlegel HB, Frisch MJ (1996) J Comput Chem 17:49–56
Peng C, Schlegel HB (1994) Israel J Chem 33:449
Petersson GA, Al-Laham MA (1991) J Chem Phys 94:6081–6090
Petersson GA, Bennett A, Tensfeldt TG, Al-Laham MA, Shirley WA, Mantzaris J (1988) J Chem Phys 89:2193–2218
Becke AD (1993) J Chem Phys 98:5648–5652
Breneman CM, Wiberg KB (1990) J Comput Chem 11:361–373
Schrodinger (2008) PHASE, Version 3.0. LLC, New York, NY
Dixon SL, Smondyrev AM, Rao SN (2006) Chem Biol Drug Des 67:370–372
Peitsch MC, Guex N (1997) Electrophoresis 18:2714–2723
Dennington R II, Keith T, Millam J, Eppinnett K, Hovell WL, Gilliland R (2003) GaussView, Version 3.09. Semichem, Shawnee Mission, KS
Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, Montgomery JA Jr, Vreven T, Kudin KN, Burant JC, Millam JM, Iyengar SS, Tomasi J, Barone V, Mennucci B, Cossi M, Scalmani G, Rega N, Petersson GA, Nakatsuji H, Hada M, Ehara M, Toyota K, Fukuda R, Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Klene M, Li X, Knox JE, Hratchian HP, Cross JB, Bakken V, Adamo C, Jaramillo J, Gomperts R, Stratmann RE, Yazyev O, Austin AJ, Cammi R, Pomelli C, Ochterski JW, Ayala PY, Morokuma K, Voth GA, Salvador P, Dannenberg JJ, Zakrzewski VG, Dapprich S, Daniels AD, Strain MC, Farkas O, Malick DK, Rabuck AD, Raghavachari K, Foresman JB, Ortiz JV, Cui Q, Baboul AG, Clifford S, Cioslowski J, Stefanov BB, Liu G, Liashenko A, Piskorz P, Komaromi I, Martin RL, Fox DJ, Keith T, Al-Laham MA, Peng CY, Nanayakkara A, Challacombe M, Gill PMW, Johnson B, Chen W, Wong MW, Gonzalez C, Pople JA (2004) Gaussian 03, Revision C.02. Gaussian, Wallingford CT
Hehre WJ, Ditchfield R, Pople JA (1972) J Chem Phys 56:2257–2261
Schlegel HB (1989) In: Bertran J (ed) New theoretical concepts for understanding organic reactions. Kluwer Academic, Dordrecht, pp 33–53
Natesh R, Schwager SLU, Evans HR, Sturrock ED, Acharya KR (2004) Biochemistry 43:8718–8724
Oefner C, Roques BP, Fournie-Zaluski MC, Dale GE (2004) Acta Crystallogr D 60:392–396
Acknowledgments
We gratefully acknowledge financial support by DST (Department of Science and Technology, New Delhi) project no. SR/S1/PC-06/2004. One of us (N. K. Rao) gratefully acknowledges DST for the Senior Research Fellowship.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Suppl. 1
Different optimised conformations of Enalaprilat (DOC 259 kb)
Suppl. 2
Bioactive Enalaprilat docked in ACE active site model (best orientation) (DOC 614 kb)
Suppl. 3
Bioactive Enalaprilat docked in ACE active site model (different orientation) (DOC 394 kb)
Suppl. 4
(DOC 25 kb)
(WMV 1536 kb)
Rights and permissions
About this article
Cite this article
Rao, N.K., Yadav, A. & Kumar Singh, S. An ab initio quantum mechanical drug designing procedure: application to the design of balanced dual ACE/NEP inhibitors. J Mol Model 15, 1447–1462 (2009). https://doi.org/10.1007/s00894-009-0500-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00894-009-0500-7